New York City, Feb. 18, 2020 (GLOBE NEWSWIRE) — As the world continues to
worry about the novel coronavirus Covid-19 and investors begin to understand
the potential impact this fast-spreading outbreak may have on China’s economy
(and, by extension, the world), Co-Diagnostics Inc. (Nasdaq:CODX), a
Utah-based molecular diagnostics company, recently announced it had tested and
launched its coronavirus test as a tool to help researchers and scientists
slow the spread of infection.

To see why this matters, let’s first take a look at the current situation:
The world’s second largest economy, considered the “factory of the world,” is
teetering. Both the disease and the containment steps enacted to control it
(the quarantining of more than 50 million people) has had a consequential
effect on businesses across disparate industries and supply chains.

Tech companies such as Apple and manufacturers of electric cars that rely on
components are beginning to worry about production slow down. Exporters
around the world are also feeling the pinch with demand for luxury items such
as Louis Vuitton, Brazilian beef and French and Chilean wine, all of which are
facing a huge drop in Chinese demand.

What’s even more worrying is that economic consequences of the virus outside
China will actually be delayed, and their significance are as yet uncertain.
Commentators believe that most effects will be felt in April. Some may well
be material and transitory – lack of certain items on store shelves, for
example, or price increases – but others could be more serious.

Spread of disease and efforts to contain it are among biggest near-term
threats to world growth, say economists. Most are forecasting that economic
growth globally this year will be reduced by 0.2% to 0.3%, while in the U.S.
first quarter growth could take a 0.2% to 0.4% hit. But some are predicting
even graver consequences.

Nassim Nicholas Taleb, a former options market broker who mistrusted the
“bell-curve” models used by many finance houses to mitigate risk, was the
first to suggest the term “Black Swan,” which is used to emphasize
unpredictable, rare events that have the potential to deeply affect financial
and global economic systems.

Yes, Brexit and other geopolitical risks such as Iran and trade wars had put
the spectre of recession and economic slowdown on the global agenda, but China
has brought forward the possibility of such a black swan scenario playing out.

One of the most important factors to mitigate and cushion the world economy
from these risks and get it back on track is the accessibility of affordable
diagnostics testing. Accurate detection and diagnosis are the first step to
combatting the spread of a disease like this, and to letting people get back
to work and travel freely again; conversely, inaccurate diagnoses lead to
healthy people being misdiagnosed and receiving expensive and unnecessary
care, and to sick people spreading the disease to their family and friends.

This is one of the reasons that Co-Diagnostics made their Logix Smart™
2019-nCoV polymerase chain reaction (PCR) tests immediately available on a
Research Use Only (RUO) basis to thousands of laboratories throughout the
world.

Dwight Egan, Co-Diagnostics CEO had this to say: “We believe the way that
Co-Diagnostics can be most helpful in this ongoing situation is by providing
diagnostic solutions that are affordable and accessible in any market in the
world. Our mandate includes supporting as many markets as possible in a public
health crisis, and taking a test from design to commercialization in under
three weeks underscores this commitment. Doing so also provides a compelling
proof-of-concept that the Company’s unique process and patented technology
could quickly and efficiently be applied to address the diagnostic needs
associated with other emergencies, including potential mutations of the
coronavirus.”

The company has stated that they are already in discussions with regulatory
bodies to gain clearance for use as an IVD, which will open up more doors in
other markets once granted, including sale within the United States.

Disclosure: Co-Diagnostics Inc is a client of BDA International.

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a
wide range of IR-related analysis, research and advisory services. In
particular, we provide and are compensated for service packages that include
strategic action plans and investor/market perception studies to help entities
improve communication with customers and investors, and to increase their
visibility. BDA International has received no direct compensation related to
this release but its principles hold shares of client companies in our
personal portfolios, including CODX. BDA International accepts sole
responsibility for the content and distribution of the foregoing release,
which does not contain any previously unpublished or non-public information.
Parties interested in learning more about the relationship between BDA and
CODX may do so via the contact information at the bottom of this release.

Disclaimer

The information, opinions and analysis contained herein are based on sources
believed to be reliable, but no representation, expressed or implied, is made
as to its accuracy, completeness or correctness. The opinions contained in
this analysis reflect our current judgment and are subject to change without
notice. We do not accept any responsibility or liability for any losses,
damages or costs arising from an investor’s or other person’s reliance on or
use of this analysis. This analysis is for information purposes only, and is
neither a solicitation to buy nor an offer to sell securities, nor a
recommendation of any security, although members of the BDA may at times hold
a position in the company covered within the article. Co-Diagnostics is a
client of BDA International. Past gains are not a representative of future
gains. The opinions herein contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements concerning manufacturing, marketing, growth,
and expansion. When used herein, the words “anticipate,” “intend,” “estimate,”
“believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and
variations of such words and similar expressions are intended to identify
forward-looking statements. Such forward-looking information involves
important risks and uncertainties that could affect actual results and cause
them to differ materially from expectations expressed herein. A company’s
actual results could differ materially from those described in any
forward-looking statements contained herein. BDA is not a licensed broker,
broker dealer, market maker, investment advisor, analyst or underwriter. We
recommend that you use the information found herein as an initial starting
point for conducting your own research in order to determine your own personal
opinion of the companies discussed herein before deciding whether or not to
invest. You should seek such investment, tax, financial, accounting or legal
advice appropriate for your particular circumstances. Information about many
publicly traded companies and other investor resources can be found at
www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:
Mushtaq Dost
BDA International
www.bda-ir.com
dost@bda-ir.com